Cure My Disease

Don't miss your cure!

 Log in / Sign up

Telecare by pharmacists may keep patients out of the hospital

NCT ID NCT07789353

Disease control Sponsor: Hospital de Clinicas de Porto Alegre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This trial tests whether a program of pharmacist-led teleconsultations, supported by digital tools, can reduce hospital readmissions for patients with chronic conditions like heart failure, diabetes, and COPD. Participants receive three phone or video consultations within 90 days of discharge, plus a messaging app for questions and a personalized care plan. The study compares this group to those receiving usual care, tracking readmissions and emergency visits over 180 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacist-led teleconsultations and digital health tools
What this could lead to
If effective, this approach could reduce hospital readmissions and urgent care visits, improving patient outcomes and easing pressure on healthcare systems.
What could go wrong
The trial is pragmatic and open-label, which may introduce bias. The intervention's success depends on patient engagement and adherence, and results may not apply to all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18 years or older; * Residing in the municipality of Porto Alegre; * Hospitalized at Hospital de Clínicas de Porto Alegre for selected Primary Care-Sensitive Conditions (PCSCs): respiratory diseases (such as asthma, chronic obstructive pulmonary disease, and tuberculosis), cardiovascular diseases (such as arterial hypertension, angina, and heart failure), cerebrovascular diseases (such as stroke), and metabolic diseases (such as diabetes mellitus). Exclusion Criteria: * Individuals who are unable to be contacted by telephone; * Individuals with language or cognitive barriers that cannot be overcome with the assistance of a caregiver or legal representative; * Individuals participating in another clinical trial that conflicts with the present study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ambulatory care sensitive conditions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ambulatory Care Sensitive Conditions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ambulatory care sensitive conditions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil